Published reports have describedthe design and synthesis of several heterocyclic and peptidic allostericTRPV1 ligands.140,141 Only one of these compounds, 7, has been investigated for its growth-inhibitory activityin human breast cancer cell lines.120 Itis hoped that other allosteric TRPV1 agonists will also be exploredfor their growth-suppressive activity in human cancers. This evidence concerns the gene TRPV1 and breast carcinoma.